Bayesian trial of adalimumab versus secukinumab for children with juvenile idiopathic arthritis associated uveitis or chronic anterior uveitis
Ramanan, Athimalaipet V Dick, Andrew D Jaki, Thomas Caruso, Gianmarco Robertson, David S Jones, Ashley P Hardwick, Ben Drake, Sian Balasubramaniam, Balini Ciurtin, Coziana
Ramanan, Athimalaipet V
Dick, Andrew D
Jaki, Thomas
Caruso, Gianmarco
Robertson, David S
Jones, Ashley P
Hardwick, Ben
Drake, Sian
Balasubramaniam, Balini
Ciurtin, Coziana
Affiliation
University Hospitals Bristol and Weston NHS Foundation Trust; University of Bristol; University College London; University of Regensburg; University of Cambridge; University of Liverpool; University Hospitals Birmingham NHS Foundation Trust; Hamburg Center for Pediatric and Adolescent Rheumatology; Ghent University Hospital; University Hospital Southampton NHS Foundation Trust; Université Paris Cité; Assistance Publique – Hopitaux de Paris; University of Florence; Meyer Children's Hospital IRCCS; Alder Hey Children's NHS Foundation Trust
Other Contributors
Publication date
2025-05-19
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Background: Juvenile idiopathic arthritis (JIA)-associated uveitis and chronic anterior uveitis in children may result in permanent sight loss. Currently, the only licensed and approved treatment for JIA-uveitis is adalimumab. However, even in patients where adalimumab may be initially effective, therapeutic response may subside for example, due to neutralising drug antibodies. Further treatment options are necessary to prevent sight loss in children with uveitis. Interleukin 17 is elevated in uveitis. Inhibition of interleukin 17 ameliorates inflammation in mouse models of uveitis. Secukinumab, an antibody which neutralizes interleukin 17 A, has been shown to be partially effective in adult uveitis. The objective of the Bayesian consensus meeting was to quantify prior expert opinion about the potential utility of secukinumab in treatment of uveitis in JIA.
Methods: Nine international experts in paediatric rheumatology, paediatric ophthalmology and/or paediatric uveitis took part in a structured Bayesian prior elicitation meeting.
Results: The final consensus was that adalimumab is expected to yield a higher response rate than secukinumab (mean 0.67 vs. 0.55). The uncertainty in the response rate on secukinumab is somewhat larger than for adalimumab. The equivalent sample size for the prior distribution of adalimumab is 15.7 and 13.1 for secukinumab. The decisions based on the combined evidence would still be driven by the trial data, yet substantial enhancement of the power of the study can be expected by adding information from the equivalent of almost 30 patients.
Conclusions: The Bayesian analysis adds substantial enhancement of the power of the study and supports a head-to-head trial of adalimumab and secukinumab for JIA-associated uveitis and chronic anterior uveitis.
Citation
Ramanan AV, Dick AD, Jaki T, Caruso G, Robertson DS, Jones AP, Hardwick B, Drake S, Balasubramaniam B, Ciurtin C, Foeldvari I, Kreps EO, Leahy A, May K, Quartier P, Robert MP, Simonini G, Guly C, Beresford MW. Bayesian trial of adalimumab versus secukinumab for children with juvenile idiopathic arthritis associated uveitis or chronic anterior uveitis. Pediatr Rheumatol Online J. 2025 May 19;23(1):55. doi: 10.1186/s12969-025-01107-1.
Type
Article